Efficacy of Dapagliflozin and Sitagliptin Phosphate Tablets in Patients with Type 2 Diabetes
Objective:To evaluate the efficacy of Dapagliflozin and Sitagliptin Phosphate Tablets in the treatment of patients with type 2 diabetes.Method:Sixty patients with type 2 diabetes admitted to the He County People's Hospital from January 2019 to December 2023 were divided into control group(n=28)and the experimental group(n=32)according to different treatment methods.The control group was treated with Dagaglipzin combined with Metformin Hydrochloride Sustained-release Tablets,and the experimental group was treated with Dagaglipzin combined with Sitagliptin Phosphate Tablets.Both groups were treated for 12 weeks,and the clinical effect,blood glucose level,body mass index(BMI),islet β cell function,lipid level and adverse reactions were compared between the two groups.Result:After treatment,the total effective rate of experimental group was 90.63%,which was higher than 67.86%of control group,and the difference was statistically significant(P<0.05).After treatment,blood glucose level,BMI,islet β cell function and blood lipid level in both groups were significantly improved compared with those before treatment,fasting plasma glucose(FPG),2 h postprandial blood glucose(2 h PG),glycated hemoglobin(HbA1c),BMI,total cholesterol(TC),triglyceride(TG),low density lipoprotein cholesterol(LDL-C)and insulin resistance index(HOMA-IR)levels of the experimental group were lower than those of the control group,the levels of high density lipoprotein cholesterol(HDL-C)and islet β cell secretion index(HOMA-β)were higher than those of control group,the differences were statistically significant(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:The combination of Dagliprazin and Sitagliptin Phosphate Tablets as a treatment for type 2 diabetes,improves glycemic control and islet beta cell function,with a good safety profile.
万方数据
维普
